A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01005823

Enrollment

Registered

2009-11-02

Start date

2009-10-31

Completion date

2010-05-31

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.

Interventions

DRUGLEO 29102 cream

Twice daily application for 7 days

DRUGLEO 29102 placebo cream

LEO 29102 placebo cream

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Age 18-55 years * Atopic dermatitis of 850-1700cm2 * In good health Criteria for exclusion: * Co-morbid conditions * Hepatic dysfunction * Clinical infection * Immunocompromised status * Clinically significant illness * Use of immunomodulating treatment * Medications related to respiratory system or to heart rhythm

Design outcomes

Primary

Measure	Time frame
Adverse events, laboratory testing, ECG, vital signs	Day 9

Secondary

Measure	Time frame
To assess the efficacy of LEO 29102 cream in the treatment of AD	Day 9

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026